Skip to main content
Article
The Food and Drug Administration Office of Women's Health: Impact of science on regulatory policy
Journal of Women's Health
  • D. Obias-Manno
  • P. E. Scott
  • Joseph M. Kaczmarczyk, Philadelphia College of Osteopathic Medicine
  • M. Miller
  • E. Pinnow
  • L. Lee-Bishop
  • M. Jones-London
  • K. Chapman
  • D. Kallgren
  • K. Uhl
Document Type
Article
Publication Date
1-1-2007
Disciplines
Abstract

In 1994, the Food and Drug Administration Office of Women's Health (FDA-OWH) was created to provide leadership and policy direction for the Agency regarding issues of women's health. Within its first year, the FDA-OWH established a science program for women's health research, promoting the development of sound policy and regulation. In a little over a decade, the program has provided approximately $14 million to fund more than 100 women's health research studies covering a broad range of health topics affecting women across their lifespan. Some studies, such as those elucidating drug effects on QT prolongation in women and drug-dietary supplement interaction, have had significant influence on regulatory decisions. Other studies have provided sound scientific data on sex and gender differences supporting FDA guidelines to protect women's health. This paper describes the science program at the FDA-OWH, providing examples of how funded research impacts regulatory policy. © Mary Ann Liebert, Inc.

Comments

This article was published in Journal of Women's Health, Volume 16, Issue 6, Pages 807-817.

The published version is available at http://dx.doi.org/10.1089/jwh.2006.0135.

Copyright © 2007.

Citation Information
D. Obias-Manno, P. E. Scott, Joseph M. Kaczmarczyk, M. Miller, et al.. "The Food and Drug Administration Office of Women's Health: Impact of science on regulatory policy" Journal of Women's Health Vol. 16 Iss. 6 (2007) p. 807 - 817
Available at: http://works.bepress.com/josephm_kaczmarczyk/9/